Focused On-demand Library for Delta-like protein 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9NR61

UPID:

DLL4_HUMAN

Alternative names:

Drosophila Delta homolog 4

Alternative UPACC:

Q9NR61; Q3KP23; Q9NQT9

Background:

Delta-like protein 4, also known as Drosophila Delta homolog 4, plays a pivotal role in the Notch signaling pathway by acting as a Notch ligand. It activates NOTCH1 and NOTCH4, and is crucial in processes such as angiogenesis, where it negatively regulates endothelial cell proliferation and migration. Furthermore, it is essential for retinal progenitor proliferation and plays a role in spinal cord neurogenesis by inhibiting V2a interneuron fate.

Therapeutic significance:

Delta-like protein 4's involvement in Adams-Oliver syndrome 6, characterized by congenital skin absence and limb defects, underscores its therapeutic significance. Understanding the role of Delta-like protein 4 could open doors to potential therapeutic strategies for treating this syndrome and possibly other Notch pathway-related conditions.